Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02326129 · ClinicalTrials.gov registry record
Novel Biomarker for Development of T2D
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 202
- Enrollment target
NCT02326129: Completed study, sponsored by Duke University.
NCT02326129 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 202 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02326129 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 202 participants
- Enrollment target
Study Summary
The investigators wants to determine if 11β-HSD1 activity will be positively associated, and 5α-reductase activity negatively associated, with (a) degree of insulin resistance defined by the homeostatic model assessment of insulin resistance index (HOMA-IR) and (b) worsening glycemic control defined by higher HbA1c and impaired fasting glucose in a group of obese children and young adults with or without type 2 diabetes compared to lean children and young adults without diabetes. The investigators also want to identify key metabolic signatures associated with diabetes using metabolomic profiling.
Primary Outcome
To assess the relationship between 11β-HSD1 and 5α-reductase activity, and measures of insulin resistance in a cohort of obese children with varying degrees of insulin resistance and glucose intolerance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2015-02 |
| Est. Completion | 2023-04-05 |
What the finished NCT02326129 record still lists
NCT02326129 is an observational study that tracks outcomes without assigning an intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02326129 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02326129 about?
NCT02326129 is a clinical study titled "Novel Biomarker for Development of T2D". The investigators wants to determine if 11β-HSD1 activity will be positively associated, and 5α-reductase activity negatively associated, with (a) degree of insulin resistance defined by the homeostatic model assessment of insulin resistance index (HOMA-IR) and (b) worsening glycemic control defined...
What is the current status of trial NCT02326129?
This trial is currently completed. The enrollment target is 202 participants. The study started on 2015-02. Estimated completion is 2023-04-05.
Who is sponsoring clinical trial NCT02326129?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia